Home » Phase II Trial Used Ambulatory Blood Pressure Monitoring to Evaluate Blood Pressure
Phase II Trial Used Ambulatory Blood Pressure Monitoring to Evaluate Blood Pressure
Eli Lilly announced that dulaglutide, its investigational, long-acting glucagon-like peptide 1 analog being studied as a once-weekly treatment for Type 2 diabetes, met its primary endpoint of non-inferiority for mean 24-hour systolic blood pressure after 16 weeks.
The Financial
The Financial
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May